Product/Composition:- | Dimenhydrinate tablets |
---|---|
Strength:- | 50 mg, 100 mg |
Form:- | Tablets |
Reference Brands:- | Dramamine(US & EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Dimenhydrinate is an antihistamine that blocks H1 receptors in the brain and inner ear, reducing nausea, vertigo, and motion sickness. It quickly alleviates symptoms, supports balance, and prevents vomiting during travel or inner ear disorders. Benefits include symptom relief, improved stability, and enhanced comfort in nausea management.
Dimenhydrinate tablets, marketed as Dramamine and generics, are approved in the US by the FDA and in the EU via EMA for preventing motion sickness, nausea, and vertigo. Regulatory approval requires a detailed dossier including clinical efficacy, safety data, manufacturing standards, and pharmacovigilance plans. The FDA reviews clinical trial and quality data for various indications, while the EMA ensures compliance with regional standards. For guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Proper adherence supports timely approval, safe use, and worldwide availability of dimenhydrinate tablets, helping manage motion sickness and nausea effectively across healthcare regions globally.